Lung Cancer

Retreatment With Checkpoint Inhibitors May Be Feasible for Some Patients With NSCLC

Increasing numbers of patients are being treated with checkpoint inhibitors, and about one-quarter to one-third will develop immune-related adverse events...

Breast Cancer

No Efficacy Difference Between Adjuvant Letrozole and Anastrozole in Postmenopausal Women With Early Breast Cancer

As reported in the Journal of Clinical Oncology by Ian E. Smith, MD, of The Royal Marsden Hospital and Institute of Cancer Research...

Issues in Oncology
Survivorship

Second Cancers May Be Deadlier in Child, Adolescent, and Young Adult Patients

Second cancers in children and adolescents and young adults (AYAs) are far deadlier than they are in older adults and may partially account for...


Advertisement

More Top Stories

Lung Cancer

Arnaud Scherpereel, MD, PhD, on Mesothelioma: Results From the IFCT-1501 MAPS2 Trial

Prostate Cancer

I Reject the Notion I’m on a Cancer Journey

I was diagnosed with stage IV prostate cancer in 2002. I had no idea the disease and its treatment would cause me to gain more than 50 pounds and nearly cripple me with pain. I had a transurethral resection of the prostate following my diagnosis and have had multiple testosterone-suppression...

Advertisement

Understanding and Managing Radiation-Induced Bystander Effect

More than half of patients with cancer undergo radiotherapy. Due to a phenomenon known as radiation-induced bystander effect, in which irradiated cells leak chemical signals that can travel some distance to damage unexposed healthy cells, many suffer side effects such as hair loss, fatigue, and...

Prostate Cancer

Tanya B. Dorff, MD, and Sumanta K. Pal, MD, on Prostate Cancer: Expert Perspectives on STAMPEDE and a Phase IV Trial

Conquer Cancer Foundation Researcher Spotlight: Dr. Supriya Mohile

SUPRIYA MOHILE, MD, MS Associate Professor of Medicine, Director of the Geriatric Oncology Clinic University of Rochester Medical Center Rochester, New York Older adults are the population most affected by cancer: 60% of all cancer occurs in this group. Yet the field of oncology that focuses...

Gideon M. Blumenthal, MD, Appointed OHOP Acting Deputy Office Director

Richard Pazdur, MD, Director of the Oncology Center of Excellence and Office of Hematology and Oncology Products (OHOP) Acting Director, has announced the appointment of Gideon M. Blumenthal, MD, as Acting Deputy Office Director of the OHOP at the U.S. Food and Drug Administration (FDA). Dr....

Analysis Reveals Genomic Alterations, Oncogenes Driving Medulloblastoma Subtypes

The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75% of the brain tumors, including two new suspected cancer genes that were found exclusively in the least understood disease subgroups. The study from an international research...

Kidney Cancer

Daniel Heng, MD, MPH, and Sumanta K. Pal, MD, on Renal Cell Carcinoma: Expert Perspectives

Myelodysplastic Syndromes

High-Risk Mutations Predict Poor Outcomes for Patients With Myelodysplastic Syndromes Undergoing Transplantation

Although several treatment options are available for patients with myelodysplastic syndromes (MDS), hematopoietic stem cell transplantation (HSCT) remains the only curative therapy.1 The risks of complications and death from transplantation can be substantial. Determining which patients may...

Advertisement

Comparison of MRI vs PET-CT in Multiple Myeloma

A study reported by Moreau et al in the Journal of Clinical Oncology indicated no difference between magnetic resonance imaging (MRI) and positron-emission tomography–computed tomography (PET-CT) in detecting bone lesions at diagnosis in patients with multiple myeloma. PET-CT normalization...